Inflammatory Myopathies

1. Inflammatory Myopathies Dipika Aggarwal, MD PGY 4 Neurology

2. Idiopathic Inflammatory Myopathies • Dermatomyositis (DM) • Polymyositis (PM) • Autoimmune Necrotizing Myopathy (NM) • Inclusion Body Myositis (IBM)

3. Idiopathic Inflammatory MyopathiesEpidemiology • Annual incidence – 1:100,000 • Incidence of individual myositides has been limited by the different diagnostic criteria employed in various epidemiological studies • IBM is the most common myopathy after age 50 with prevalence of 3.5/100,000 cases • Disease of adults (except for Juvenile DM) • Women are more commonly affected • Genetic predisposition secondary to inherited Human Leukocyte Antigens (HLA) haplotypes

4. Idiopathic Inflammatory Myopathies

5. Idiopathic Inflammatory Myopathies

6. Dermatomyositis (DM) • Can present at any age, including infancy • Affects female more than males • Acute (over several weeks) or insidiously (over months) progressive, painless, proximal weakness with or without characteristic skin rash • Proximal leg and arm muscles are usually the earliest and most severely affected muscle groups • Mostly painless • Speech, chewing and swallowing difficulties may be seen • JDM commonly presents after a febrile episode and with a skin rash • Multisystem involvement is more common in JDM

7. Dermatomyositis: Skin involvement • Distinct rash • Occurs before or with the onset of muscle weakness • Variable degree of muscle versus skin involvement • Amyopathic DM– isolated rash with no muscle involvement • AdermatopathicDM – isolated myositis • Classical DM findings: • heliotrope rash • Gottron’s papules • dilated nail bed capillaries • V-sign • shawl sign • mechanic’s hands • Subcutaneous calcinosis seen in 30-70% cases of JDM, less common in adults

8. DM : Skin findings Heliotrope rash: purplish discoloration along the hairline of scalp and malar region of the face and eyelids Dilated capillary loops evident in the nail bed as well as small ulceration involving the distal aspect of the little finger

9. DM : Skin findings Gottron papules : erythematous lichenoidpapular scaly rash, over the extensor surface of the hands and fingers

10. DM : Skin findings V sign: Erythematous rash around face, neck and anterior chest Shawl sign: erythematous rash affecting upper back

11. DM : Skin findings Mechanic’s hands: Cracking of the finger pad skin, commonly involving the first, second, and third fingers

12. Dermatomyositis – Lab features • Serum CK • Elevated serum CK with levels ranging upto 50 times the upper limit of normal • CK level may be normal in less than 10% pts • Do not co-relate with the severity of weakness • ANA is detected in 24-60% of pts with DM • Myositis specific antibodies • Found in a minority of patients • Useful in predicting response to therapy and prognosis • Cytoplasmic antibodies directed against transitional proteins (tRNAsynthetases and anti-signal recognition particle) • Directed against nuclear proteins (Mi-2 and Mas antigens) • Most common MSA are Jo-1 antibodies, associated with Interstitial Lung Disease, seen in 20% pts (MTX should be avoided) • Mi-2 antibodies (15-20% DM pts); associated with acute onset, florid rash, good response to therapy and favourable prognosis

13. Dermatomyositis - Electrophysiology • Motor and sensory nerve conduction studies are mostly normal • Needle examination shows non specific findings of irritative myopathy (increased insertional activity, fibrillation potentials and positive sharp waves, complex repetitive discharges) • Muscle fibrosis in advanced cases may result in reduced insertionalactivity due to fibrosis • Motor unit action potentials (MUAPs) are polyphasic, brief, and of low amplitude • EMG is helpful in assessing relapsing weakness during treatment • Worsening strength in the absence of fibrillation potentials suggests a steroid induced myopathy

14. DermatomyositisHistopathology and Pathogenesis • Histology • Earliest finding : Membrane Attack Complexes around blood vessels • Pathognomic : perifascicularatrophy with or without perimysial and perivascular inflammatory infiltrate (macrophages , B cells , CD4+ T cells , plasmacytoid dendritic cells) • Electron microscopy: tubulo reticular inclusions in the intramuscular arterioles and capillaries • Pathogenesis • Humorally mediated micro angiopathy • antibodies directed against endothelial cells activate complement factors  membrane attack complex (MAC) deposition on capillaries  endothelial damage, capillary necrosis, perivascular inflammation, ischemia and myofibril necrosis

15. Muscle Biopsy Perifascicular atrophy with perimysial inflammation MAC deposition around blood vessels (Immunoperoxidase stain)

16. Muscle Biopsy

17. Idiopathic Inflammatory Myopathies

18. Polymyositis (PM) • Exclusionary diagnosis in pts who do not have a rash or alternate muscle or nerve disease • PM is a disease of adults over age 20 years • More prevalent in female • Subacute to insidiously progressive, proximal arm and leg weakness • Myalgias and tenderness are common but usually not the first presenting symptoms • Dysphagia is seen in one-third of patients • Facial weakness is occasionally present

19. Polymyositis – work up • Elevated CK in range of 5 to 50 times the normal. Unlike DM, CK is always elevated in PM • Positive ANA (16-40% ) • Myositis specific antibodies • useful in predicting response to therapy and prognosis • Anti SRP antibodies:severe, fulminant, steroid resistant PM • Anti Jo-1 antibodies: associated with ILD • Electro diagnostic tests show evidence of muscle irritation • Increased insertional activity, positive sharp waves, polyphasic MUAPs • Do not distinguish PM from other IIM • Skeletal muscle MRI – increased signal consistent with muscle edema and inflammation

20. Polymyositis Histopathology and Pathogenesis • Histology • fiber size variability • scattered necrotic and regenerating fibers • endomysialinflammation consisting of cytotoxic T cells and macrophages • Pathogenesis • HLA- restricted, antigen specific, cell mediated immune response directed against muscle fibers • ?? Trigger • viral infections (inconclusive hypothesis) • MHC 1 expressed endogenous peptide “auto antigen”  activation of CD8+ cytotoxic T cells and macrophages that invade myocytes destroy muscle fibres through perforin pathway causing pore formation and osmolysis • Unlike DM - MAC, complement or immuno globulins are not deposited on the microvasculature in PM

21. Muscle Biopsy Endomysial inflammatory cell infiltrate surrounding and invading non necrotic muscle fibres

22. Idiopathic Inflammatory Myopathies

23. Autoimmune Necrotizing Myopathy (NM) • Increasing recognized autoimmune myopathy • little or no inflammatory infiltrate • more common in females • sub acute progressive proximal weakness without rash • rapid onset than PM; markedly severe in 30% cases • myalgia and dysphagia

24. Autoimmune Necrotizing MyopathySubtypes • Paraneoplastic NM • rare, rapidly progressive • severe variant • associated with adenocarcinoma • NM with thick “pipestem” capillaries • associated with subacuteweakness • brain infarction due to vascultis • Connective Tissue Disease • SRP autoantibodies associated NM • Severe, fulminant • treatment refractory • cardiac complications (myocarditis) • Statin induced autoimmune NM (SANAM) • affects between 46 to 89 year old pts • onset may be delayed upto 10 yrs following statin initiation • may occur several months after discontinuation • Often therapy resistant

25. Autoimmune Necrotizing Myopathy – work up • Elevated CK – more than 10 times the normal • Positive ANA – suggestive of underlying CTD • MSA – SRP autoantibodies • EMG – irritative myopathy

26. NM - Histopathology and Pathogenesis • Histology • Scattered necrotic myofiberswith myophagocytes • Absence or paucity of T-lymphocytic inflammation • Unlike DM, perivascular inflammation is scant, and there are no endothelial tubulo reticular inclusions • Thick-walled and enlarged “pipestem” capillaries is diagnostic of NM with pipestemcapillaries • SRP-associated NM: bimodal distribution of fiber sizes, increased endomysial connective tissue, and reduced endomysial capillary number with enlargement and thickening • Pathogenesis • Unknown • deposition of complement MAC on small arterioles and capillaries with thickened endothelial walls suggests humorallymediated microangiopathy • Anti 200/ 100 antibodies • Autoantigen is 3-hydroxy -3- methylglutaryl-coenzyme A reductase (HMGCR) protein • Statin upregulate HMGCR protein levels, thus triggering anti- HMGCR auto immunity

27. Muscle Biopsy Scattered necrotic fibers, some undergoing phagocytosis

28. Associated conditions • There is an increased incidence of interstitial lung disease, autoimmune disorders, cancer and cardiac disorders in patients with DM , PM and NM • Cardiac • conductions defects, arrhythmias • ventricular and septal wall motion abnormalities • Pericarditis and congestive heart failure (less common) • Myocarditis (seen in 1/3rdpts), associated SRP autoantibodies • Pulmonary • 10-25% of patients have ILD • Jo-1 antibodies are present in at least 50% of ILD cases • Prompt chest imaging and pulmonary function tests • Pulmonary consultation

29. Associated conditions (contd.) • Malignancy • Most studies suggest 15 to 25% of adult DM patients, older than 40 years, have preexisting, concurrent, or future malignancies • Most common DM-associated malignancy • Women: ovarian cancer • Men: small cell lung cancer • Other common malignancies are – pancreatic cancer, stomach and colorectal cancers and lymphoma • Rarely, malignancy has been reported in JDM • Malignancy is increased in PM and NM when compared with the general population • Routine screening with careful skin examination for melanoma; CT scan of chest, abdomen and pelvis; and in women, mammogram and pelvic exam; in men, testicular and prostate examinations • If primary screening is negative, repeat screening is recommended after 3-6 months; thereafter every 6 months for 4 years • Treatment of the malignancy improves muscular involvement

30. Associated conditions (contd.) • Gastro-intestinal system • Dysphagia, aspiration and delayed gastric emptying due to smooth and skeletal muscle weakness • Vasculopathy affecting the GI tract may cause bowel ischemia, necrosis and perforation more commonly seen in JDM • Joints • Polyarthritis has been reported in up to 45% of patients with PM

31. Treatment Immunosuppressive therapy is the mainstay of treatment

32. First line: Corticosteroids • No controlled trails • Usual dosing schedule • 1mg/kg/day or 60-100mg daily for 2-4 weeks followed by every other day schedule • Slower taper in more severe disease • Intravenous steroids may be used in more severe cases initially followed by a slower taper • response to therapy seen in 2-3 months • no improvement is seen in 4-6 months or concerns for side effects or exacerbation during the taper , add second line agents • Special points • CXR, PPD – screening; if PPD positive initiate Rx with isoniazid • DEXA at baseline and every 6 months; if bone density < 1.0 SD initiate Rx with alendronate

33. Second line of managementSteroid sparing agents

34. Second line of managementSteroid sparing agents

35. Third line • Cyclosporine • Dose: 3 to 4 mg/kg per day; max 6mg/kg/day • C/I: HTN, renal dysfunction, malignancy, pregnancy • S/E: HTN, renal failure, gingival hyperplasia, GI upset • Monitor BP, renal function, drug level • Tacrolimus • Dose: 2mg oral titrated to clinical response/ tolerance • C/I: ILD and Anti Jo-1 antibodies, renal/ hepatic impairement • S/E: diarrhea, headache, tremors, insomnia, lymphoma • Cyclophosphamide • Dose: 1-2mg/kg per day • C/I: myelosuppression, pregnancy • S/E: hemorrhagic cystitis, alopecia, GI upset • High fluid intake, monitor UA and CBC closely • Recent drug trials • Etanercept • Rituximab

36. Recent drug trialsRandomized, Pilot Trial of Etanercept in Dermatomyositis; Muscle Study Group (Amato, et al) Neurology 2011 • Etanercept: Tumor necrosis factor α inhibitor • Randomized, double blind, placebo controlled trial • 16 subjects randomized: 11 – etanercept; 5 – placebo • Duration of study: 52 weeks • Etanercept: 50 mg subcutaneous weekly • All subjects tapered off prednisone over 24 weeks • Outcome measures: adverse events, time from randomization to failure, average prednisone dose at 24 weeks • Results: • All 5 Placebo subjects: failed (median 148 days) • 6/11 Etanercept subjects: failed (median 358 day) • 5/11 Etanercept subjects: successfully tapered off Prednisone • Average prednisone dosage after 24 weeks lower in etanercept group (1.2mg/day) as compared to placebo group (29.2mg/day) • Conclusion: Etanercept may have steroid sparing effect; need further study

37. Recent drug trialsRituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis. Oddis et al, 2011 • Rituximab: B cell depleting agent • Randomized, double blind, placebo phase trial • 195 subjects with refractory disease (76 PM, 76 DM and 48 JDM) • Duration of study: 44 weeks • 2 groups: • Group A ( Rituximab early) • Group B ( Rituximab started 8 weeks later) • Outcome measures: • Primary end point: time to achieve definition of improvement • Secondary end point: time to achieve 20% improvement in muscle strength • Results • No significant difference in Group A and B in primary end point (20.2 and 20 weeks respectively) • No difference in secondary end point • 83% of subjects met the primary end point/ DOI following Rituximab treatment • Conclusion: The role of B cell depleting therapies in myositis warrants further study

38. Other therapies • Diet and lifestyle • Dietary supplementation has limited role • Oral creatine may be of potential benefit • Assistive devices • Single prong cane, Rolling walker, wheelchair to prevent falls • Physical therapy • To maintain strength and address ADLs • Early mobilization to prevent flexion contractures of large joints

39. Prognosis • The prognosis of the idiopathic inflammatory myopathies is generally favorable • Overall, drug-free remissions are rare except in JDM • Poor prognostic factors • old age • male gender • non-Caucasian ethnicity • longer symptom duration • ILD, cardiac involvement • associated malignancy • dysphagia • serum MSA (anti Jo-1 antibodies, anti SRP antibodies) • Mortality remains two- to three fold higher than the general population; with cancer, lung, cardiac complications, and infections being the most common causes of death

40. Idiopathic Inflammatory Myopathies

41. Inclusion body myositis (IBM) • Most common inflammatory myopathy after age 50 yrs • Insidious onset, slowly progressive proximal leg and distal arm weakness • Delayed diagnosis with average duration of symptoms prior to diagnosis is 6-7 yrs • Male are affected more than female • Hallmark: weakness and atrophy (2/3rdof the pts) • Legs: knee extensors, ankle dorsiflexors • Arms: wrist and finger flexors • Upto 82% of patients have marked asymmetry • Sparing of thenar and hypothenar muscles helps distinguish IBM from ALS • Dysphagia occurs on 70% patients • Mild to moderate facial weakness

42. IBM marked difficulty in flexing the fingers of the left hand as compared to the right Quadriceps atrophy

43. IBM – work up • Serum CK may be normal or elevated up to 10 times normal • ANA positive in 20% patients • Nerve conduction studies - mild sensory axonal peripheral polyneuropathy in up to 30% of patients with IBM • Needle examination - evidence of muscle irritation (increased insertional activity, positive sharp waves, polyphasicpotentials) • Skeletal muscle MRI scans – atrophy and signal abnormalities in affected muscle groups

44. IBM - Histopathology and Pathogenesis • Histology • Endomysial inflammation • Small group of atrophic fibers • Eosinophilic cytoplasmic inclusions ( better visualized with immunostain directed against phosphorylated tau) • Multiple myofibers with one or more rimmed vacuoles lined with granular material (likely amyloid deposition-Congo Red stain) • Pathogenesis ; unknown • Autoimmune - presence of inflammatory cells on histology (cytotoxic T cells, myeloid dendritic cells, B cells and IBM autoantibody) • Degenerative - no response to immunotherapy, presence of protein aggregates (amyloid, hyperphosphorylated tau, neurofilament heavy chain) within rimmed vacuolated muscle fibers

45. Muscle Biopsy H&E stain Vacuole filled with granules (Modified Gomoritrichromestain)

46. Treatment • Refractory to all treatments • Various RCT of IVIg with or w/o steroids, MTX, beta interferon, etanercept did not show any benefit • Some patients may have transient and mild improvement with corticosteroids and exercise therapy early on in the course of the disease • Several novel therapies are being evaluated – lithium chloride, arimoclomol, follistatin gene transfer therapy • Arimoclomol: potent heat shock protein 70 inducer • Inducing HSP levels may reverse the toxic cellular changes • Recent two-center trial (KU and University College London) was conducted to assess the safety and tolerability of Arimoclomol in IBM as compared to placebo over 4 months of treatment • Arimoclomolis well tolerated in this study population

47. Prognosis • Associated conditions • Unlike DM &PM, IBM is not associated with myocarditis, lung disease and malignancy • 15% pts have underlying autoimmune CTD like SLE, Sjogren’s, Scleroderma and sacrcoidosis • Prognosis • Life expectancy not significantly altered • Most patients are wheelchair bound by 10-15 years

48. References • Dimachkie MM, Barohn RJ. Idiopathic inflammatory myopathies. Semin Neurology 2012; 32:227-236 • Dimachkie MM, Barohn RJ. Inclusion Body Myositis. SeminNeurology 2012; 32:237-245 • Dimachkie MM. Idiopathic Inflammatory Myopathies. Journal of Neuroimmunology 231 (2011): 32-42 • Amato AA, Russell JA. Inflammatory Myopathies. Neuromuscular Disorders 2008; Chapter 30: 681-713 • Distad BJ, Amato AA. Inflammatory myopathies. Current Treatment Options in Neurology (2011) 13: 119-130 • Oddis CV, Reed AM. Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis. Athritis and Rheumatism, 2013, Vol 65, 314-324 • Amato AA. Randomized, Pilot Trial of Etanercept in Dermatomyositis; Muscle Study Group. Neurology 2011; 70: 427-436 • Dalakas MC, Hohlfeld R. Polymyostis and Dermatomyositis. The Lancet 2003; Vol 362: 971-982 • Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumoursin paraneoplasticsyndromes: report of an EFNS task force. EurJ Neurol2011;18(1):19–e3 • Amato AA, Barohn RJ. Evaluation and treatment of inflammatory myopathies. J NeurolNeurosurg Psychiatry 2009; 80: 1060 – 1068 • http://neuromuscular.wustl.edu • Miller FW. Myositis-specific autoantibodies: touchstones for understanding the inflammatory myopathies. JAMA 1993;270:1846-1849